Uniqure NV 8-K filings

uniQure has completed the sale of its Lexington manufacturing facility to Genezen, resulting in a significant reduction in cash burn and continued access to manufacturing capabilities.

uniQure's AMT-130 gene therapy shows significant slowing of Huntington's disease progression and reduction in a key neurodegeneration marker in interim Phase I/II trial data.

uniQure has agreed to sell its Lexington, Massachusetts manufacturing facility to Genezen for $25 million, aiming to reduce cash burn by $40 million annually and streamline operations.

uniQure N.V. shareholders approved an amendment to the 2014 Share Incentive Plan, increasing the number of shares available for issuance, and re-elected two non-executive directors at the 2024 Annual General Meeting.

uniQure's investigational gene therapy, AMT-130, for Huntington's disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.

uniQure announced its first quarter 2024 financial results, highlighting progress in clinical trials and strategic cost management.

Paula Soteropoulos, a non-executive director at uniQure N.V., will not stand for re-election at the company's 2024 annual meeting.

uniQure reports its 2023 financial results, highlights clinical progress, and announces a strategic reorganization to achieve $180 million in cost savings over three years.